GleamWall
中文EN

TNGX Tango Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1819133 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY121.5%
TTM net income YoY15.0%
TTM EPS YoY36.4%
Revenue 3-yr CAGR16.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-253.4%
Net margin-229.9%
FCF margin-268.1%
EBITDA margin-249.8%

Returns

ROE-21.3%
ROA-18.9%
ROIC (approx.)-28.5%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets4.6%
Debt / equity0.00x
Current ratio50.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$53.81M$3.18M$5.39M$4.12M
R&D expense$48.93M$37.20M$33.53M$32.10M$30.82M$32.81M$36.44M$33.94M
SG&A expense$29.19M$22.59M$15.23M$9.76M$8.92M$11.34M$11.48M$11.09M
Operating income-$78.12M-$59.78M-$48.77M-$41.86M$14.07M-$40.97M-$42.53M-$40.91M
Pretax income-$68.39M-$55.34M-$45.51M-$38.80M$15.87M-$38.82M-$39.84M-$37.62M
Income tax$0$1,000$1,000-$55,000-$10,000$35,000$34,000$49,000
Net income-$68.39M-$55.34M-$45.51M-$38.75M$15.88M-$38.85M-$39.88M-$37.67M
EBITDA-$77.70M-$59.36M-$48.31M-$41.38M$14.63M-$40.34M-$41.91M-$40.29M
EPS (basic)-0.39-0.37-0.32—0.14-0.35-0.36—
EPS (diluted)-0.39-0.37-0.32—0.13-0.35-0.36—
Weighted avg. shares (diluted)173.93M149.88M143.58M—117.78M110.54M110.30M—
Banking
Net interest income$7.15M$3.72M$2.18M$1.68M$1.10M$1.24M$1.61M$1.81M
Balance sheet
Cash & equivalents$86.83M$345.56M$157.83M$112.28M$58.34M$58.34M$58.43M$69.53M
Short-term investments$890.67M$668.43M$222.01M$230.86M$94.47M$141.51M$158.29M$188.39M
Current assets$992.66M$1.03B$392.33M$353.76M$163.78M$190.10M$224.93M$266.34M
PP&E, net$5.75M$6.09M$6.38M$6.87M$7.35M$7.79M$7.54M$8.10M
Total assets$1.03B$1.07B$435.79M$398.69M$210.14M$237.89M$274.31M$316.49M
Current liabilities$25.16M$20.30M$14.33M$21.68M$18.44M$40.02M$35.92M$38.17M
Total liabilities$53.29M$49.35M$44.29M$52.51M$50.10M$102.94M$107.55M$116.97M
Shareholders' equity$980.17M$1.02B$391.51M$346.18M$160.03M$134.95M$166.76M$199.52M
Shares outstanding169.21M168.38M144.16M135.94M111.57M110.87M108.11M107.73M
Cash flow statement
Operating cash flow-$37.14M-$38.87M-$44.36M-$29.72M-$30.95M-$36.52M-$41.70M-$36.65M
Capital expenditure$77,000-$20,000-$2,000$222,000$151,000$624,000$51,000$124,000
Free cash flow-$37.22M-$38.85M-$44.36M-$29.94M-$31.10M-$37.14M-$41.75M-$36.77M
Investing cash flow-$223.98M-$445.97M$9.63M-$135.72M$47.48M$16.78M$30.60M$52.06M
Financing cash flow$2.40M$672.57M$79.85M$219.38M$2.54M$581,000$2,000$969,000
Depreciation & amortization$420,000$425,000$463,000$479,000$555,000$625,000$622,000$620,000
Stock-based compensation$24.91M$16.89M$10.80M$5.98M$6.62M$6.57M$7.25M$7.46M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.